This product is a recombinant mouse antibody clone TIB-141, which specifically binds to Gal9.
Figure 1 Effects of Gal-9 on degranulation and MAPK activation in RBL-2H3 cells.
A, RBL-2H3 cells cultured in 96-well plates (2× 10⁴ cells/well) were stimulated by the addition of TIB-141 and TNP-BSA. hG9Null and mG9Null were added 10 min before the stimulation. β-HEX activity was determined in the culture medium, and a cell lysate was prepared 60 min after the stimulation. The horizontal broken line represents the mean value for a control sample (without TIB-141 and TNP-BSA). Lactose was used at a concentration of 20 mM. The data shown in A are derived from a single representative experiment of two independent experiments. The results are presented as means±S.D.(error bars) (n=3). B, RBL-2H3 cells cultured in 12-well plates (2.5×10⁵ cells/well) were treated. hG9Null and mG9Null were used at 0.3 and 1 μM, respectively. A whole cell lysate was prepared at the time points indicated after the addition of TIB-141 and TNP-BSA. Samples were electrophoretically separated in SDS-12.6% polyacrylamide gels under reducing conditions (5 μg/lane), blotted onto PVDF membranes, and then subjected to immunodetection using anti-phospho-p44/42 MAPK (Erk1/2) (Thr²⁰²/Tyr²⁰⁴), anti-p44/42 MAPK, and anti-actin antibodies.
Nakakita, S. I., Itoh, A., Nakakita, Y., Nonaka, Y., Ogawa, T., Nakamura, T., & Nishi, N. (2016). Cooperative interactions of oligosaccharide and peptide moieties of a glycopeptide derived from IgE with galectin-9. Journal of Biological Chemistry, 291(2), 968-979.
Figure 2 Effect of peptides derived from the affinity-purified lysyl endopeptidase digest of PE-TIB-141 on Gal-9-induced suppression of degranulation.
HPLC peak fractions derived from 3.0 nmol (A and B) or 15 nmol (C) of PE-TIB-141 were examined for their ability to antagonize G9Null. The peak fractions were lyophilized and then dissolved in 50 μl of PBS. The peptide solutions (25 μl) were mixed with G9Null solutions (225 μl), followed by 30-min incubation at room temperature before adding to the RBL-2H3 cell culture. The data are derived from a single representative experiment of two independent experiments. The results are presented as means±S.D. (error bars) (n=3).
Nakakita, S. I., Itoh, A., Nakakita, Y., Nonaka, Y., Ogawa, T., Nakamura, T., & Nishi, N. (2016). Cooperative interactions of oligosaccharide and peptide moieties of a glycopeptide derived from IgE with galectin-9. Journal of Biological Chemistry, 291(2), 968-979.
Figure 3 Analysis of peptides derived from the affinity-purified lysyl endopeptidase digest of PE-TIB-141 by SDS-PAGE and MALDI-TOF MS.
A, P4 –P23 preparations were incubated overnight at 37 °C in the absence (C) or presence (G) of peptide-N-glycosidase F and then analyzed by SDS-PAGE (13.5% polyacrylamide gel) under reducing conditions. The gels were stained with Coomassie Brilliant Blue R-250. B, the selected band materials subjected to N-terminal amino acid sequence analysis are indicated. C, MALDI-TOF mass spectrum of the P23 preparation treated with peptideN-glycosidase F. The sample was applied onto a ground steel target using sinapinic acid as a matrix.
Nakakita, S. I., Itoh, A., Nakakita, Y., Nonaka, Y., Ogawa, T., Nakamura, T., & Nishi, N. (2016). Cooperative interactions of oligosaccharide and peptide moieties of a glycopeptide derived from IgE with galectin-9. Journal of Biological Chemistry, 291(2), 968-979.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
CAT | Product Name | Application | Type |
---|---|---|---|
MOB-3377z | Mouse Anti-LGALS9 Recombinant Antibody (clone 30D5) | WB, IP, IF, ELISA | Mouse IgG2b, κ |
FN-143CQ | Recombinant Rat Anti-LGALS9 Antibody (CBL-1312) | FuncS, Block | Rat IgG2a, κ |
VS-0723-WK172 | Human Anti-LGALS9 Recombinant Antibody (VS-0723-WK172) | FC | Chimeric (rabbit/human) IgG1 |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-039CQ | Mouse Anti-LGALS9 Recombinant Antibody (TAB-039CQ) | IHC, ELISA, WB | Mouse IgG1, κ |
TAB-042CQ | Mouse Anti-LGALS9 Recombinant Antibody (TAB-042CQ) | ELISA, FC, WB, Neut | Mouse IgG1, κ |
TAB-039CQ-S(P) | Mouse Anti-LGALS9 Recombinant Antibody; scFv Fragment (TAB-039CQ-S(P)) | ELISA, FC, WB, Neut | Mouse scFv |
TAB-042CQ-S(P) | Mouse Anti-LGALS9 Recombinant Antibody; scFv Fragment (TAB-042CQ-S(P)) | ELISA, FC, WB, Neut | Mouse scFv |
TAB-039CQ-F(E) | Mouse Anti-LGALS9 Recombinant Antibody; Fab Fragment (TAB-039CQ-F(E)) | ELISA, FC, WB, Neut | Mouse Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-040CQ | Human Anti-LGALS9 Recombinant Antibody (TAB-040CQ) | ELISA, FC, WB, Neut | Human IgG1, κ |
TAB-043CQ | Human Anti-LGALS9 Recombinant Antibody (TAB-043CQ) | ELISA, FC, WB, Neut | Human IgG1, κ |
TAB-040CQ-S(P) | Human Anti-LGALS9 Recombinant Antibody; scFv Fragment (TAB-040CQ-S(P)) | ELISA, FC, WB, Neut | Human scFv |
TAB-043CQ-S(P) | Human Anti-LGALS9 Recombinant Antibody; scFv Fragment (TAB-043CQ-S(P)) | ELISA, FC, WB, Neut | Human scFv |
TAB-040CQ-F(E) | Human Anti-LGALS9 Recombinant Antibody; Fab Fragment (TAB-040CQ-F(E)) | ELISA, FC, WB, Neut | Humanized Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-044CQ | Human Anti-LGALS9 Recombinant Antibody (TAB-044CQ) | ELISA, FC, WB, Neut | Chimeric (Mouse/Human) IgG1, κ |
TAB-041CQ-S(P) | Human Anti-LGALS9 Recombinant Antibody; scFv Fragment (TAB-041CQ-S(P)) | ELISA, FC, WB, Neut | Human scFv |
TAB-044CQ-S(P) | Human Anti-LGALS9 Recombinant Antibody; scFv Fragment (TAB-044CQ-S(P)) | ELISA, FC, WB, Neut | Human scFv |
TAB-041CQ-F(E) | Human Anti-LGALS9 Recombinant Antibody; Fab Fragment (TAB-041CQ-F(E)) | ELISA, FC, WB, Neut | Chimeric (Mouse/Human) Fab |
TAB-044CQ-F(E) | Human Anti-LGALS9 Recombinant Antibody; Fab Fragment (TAB-044CQ-F(E)) | ELISA, FC, WB, Neut | Chimeric (Mouse/Human) Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
NEUT-1688CQ | Recombinant Mouse Anti-LGALS9 Antibody (9S2-1) | WB, Neut | IgG1, κ |
CAT | Product Name | Application | Type |
---|---|---|---|
NEUT-1690CQ | Recombinant Rat Anti-Lgals9 Antibody (RG9-1) | BL | IgG2b |
CAT | Product Name | Application | Type |
---|---|---|---|
FAMAB-0208CQ-F(E) | Mouse Anti-LGALS9 Recombinant Antibody (clone TIB-141); Fab Fragment | WB | Mouse Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
FAMAB-0208CQ-S(P) | Mouse Anti-LGALS9 Recombinant Antibody (clone TIB-141); scFv Fragment | WB | Mouse scFv |
There are currently no Customer reviews or questions for FAMAB-0208CQ. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.